

276

**Current Topics
in Microbiology
and Immunology**

Editors

R.W. Compans, Atlanta/Georgia

M.D. Cooper, Birmingham/Alabama · Y. Ito, Singapore

H. Koprowski, Philadelphia/Pennsylvania

F. Melchers, Basel · M.B.A. Oldstone, La Jolla/California

S. Olsnes, Oslo · M. Potter, Bethesda/Maryland

P.K. Vogt, La Jolla/California · H. Wagner, Munich

Springer-Verlag Berlin Heidelberg GmbH

A. STEINKASSERER (Ed.)

Dendritic Cells and Virus Infection

With 24 Figures and 2 Tables



Springer

PROF. DR. ALEXANDER STEINKASSERER

Dermatologische Klinik

Universität Erlangen

Hartmannstr. 14

91052 Erlangen

Germany

e-mail: steinkasserer@derma.imed.uni-erlangen.de

Cover Illustration by S. Schneider Schaulies (this volume):

Schematic Representation of the MV Particle

ISSN 0070-217X

ISBN 978-3-642-07926-9

ISBN 978-3-662-06508-2 (eBook)

DOI 10.1007/ 978-3-662-06508-2

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag Berlin Heidelberg GmbH. Violations are liable for prosecution under the German Copyright Law.

<http://www.springer.de>

© Springer-Verlag Berlin Heidelberg 2003

Originally published by Springer-Verlag Berlin Heidelberg New York in 2003

Softcover reprint of the hardcover 1st edition 2003

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting other relevant literature.

Cover Design: *design & production GmbH*, Heidelberg

Production Editor: Angélique Gcouta

Preface

In the first part of this volume the interactions between Dendritic cells (DCs) and several viruses will be presented and discussed.

DCs are the best antigen presenting cells (APCs) known to date, and since DCs are the only APCs able to induce naïve T cells they are also known as “nature’s adjuvant”. Thus, DCs play a crucial role in the induction of anti-viral immune responses. On the other hand, many viruses are capable of developing a vast armamentarium in order to interfere with DC-biology, thereby blocking anti-viral immune responses. DCs often play a dual role in viral infections, influencing both pathogenesis as well as protective mechanisms. This has been shown, for instance, in the case of HIV-1 and SIV, where HIV-1 infects selected DC-populations. In addition HIV-1 uses DCs as a vector to reach the lymphoid tissues where they infect T cells. The cell surface molecule DC-SIGN has been identified as such a DC-specific HIV-1 receptor, which plays a key-role in the dissemination of HIV-1 by DCs. On the other hand, DCs are efficient APCs for HIV-1 and SIV antigens to both CD4⁺ and CD8⁺ T cells. In addition DCs can cross-present non-replicating viral antigens on class I MHC molecules, thereby allowing the stimulation of CD8⁺ T cells after the uptake of anti-body-coated HIV-1 and dying infected T cells.

DCs also play a crucial role in Epstein-Barr virus (EBV) infection. There is growing evidence that DCs, and not EBV-transformed B cells, are responsible for protective antiviral immunity and that EBV nuclear antigen 1 (EBNA1) is the crucial antigen regarding the resistance against all types of EBV-associated malignancies.

Measles virus (MV) infection is the major cause of childhood mortality in developing countries and is accompanied by a severe immunosuppression of the infected host. However, virus-specific immunity is efficiently induced, leading to viral clearance and long-term induction of protective immunity. On the one hand, DCs play a crucial role in the induction of anti-viral immune responses, while on the other hand MV infects DCs, thereby interfering with DC biology. Inhibition of stimulated IL-12 production from MV-infected DCs might affect T cell responses and favour Th2 and suppressing Th1 responses. In addition, viral protein expressed on the cell surface of infected DCs most likely also inhibit T cell responses.

DCs also express the receptor (α -dystroglycan) for lymphocytic choriomeningitis virus (LCMV), Lassa fever virus (LFV) and several other arenaviruses. It has been shown that LCMV strains which bind to the receptor with high affinity replicate in the majority of DCs, causing a generalized immunosuppression, and establish a persistent infection. This immune suppression is caused by the loss of MHC class II molecules and costimulatory molecules on the cell surface of the DCs. Furthermore, the migratory capacity of DCs is hampered by LCMV infections. It is noted, however, that LCMV strains which bind with low affinity rarely replicate in DCs, and generate a potent anti-LCMV response, which is able to clear the infection.

HSV-1 is a further example of a virus which down-modulates DC functions by interfering with the expression of DC specific molecules such as CD83. In fact, CD83 is completely degraded in HSV-1 infected DCs, which coincides with a clearly reduced T cell stimulation, representing yet another new escape strategy.

The second part of this volume concentrates on DC-specific strategies in order to strengthen antiviral immune responses.

DC-based vaccination strategies represent one of the most promising approaches for the immunotherapy of cancer and infectious diseases. Several clinical trials have already been performed showing only minimal toxicity in tumor patients. Both induction of antigen specific T cells as well as some clinical responses have been reported using this strategy, even in far advanced tumor patients. Nevertheless, DC-based immunotherapy is still at an early stage and many variables have still to be addressed. However, the increasing knowledge of DC biology will help to improve and further develop this new strategy.

Data derived from animal models, regarding the induction of LCMV-specific immunity with various DC-vaccination approaches will be discussed. In addition, the interplay between human papillomaviruses (HPV) and DCs will be presented. Here, DCs (including Langerhans cells) are pivotal for the induction of T cell dependent immunity. This, however, depends exclusively on cross-presentation of viral antigens by DCs. This exogenous pathway of MHC class I-restricted antigen presentation plays an important role in the generation of antiviral immunity against several viruses. Finally, viral vectors which could be used for DC-based immunotherapy will be presented and their advantages and disadvantages will be discussed respectively.

List of Contents

Part 1: Interaction of Dendritic Cells and Viruses

The Interaction of Immunodeficiency Viruses with Dendritic Cells. R. STEINMAN, A. GRANELLI-PIPERNO, M. POPE, C. TRUMPFHELLER, R. IGNATIUS, G. ARRODE, P. RACZ, and K. TENNER-RACZ	1
--	---

DC-SIGN: A Novel HIV Receptor on DC that Mediates HIV-1 Transmission T.B.H. GEIJTENBEEK and Y. VAN KOOYK	31
--	----

Contrasting Roles of Dendritic Cells and B Cells in the Immune Control of Epstein-Barr Virus K. BICKHAM and C. MÜNZ	55
---	----

Dendritic Cells and Measles Virus Infection S. SCHNEIDER-SCHAULIES, I.M. KLAGGE, and V. TER MEULEN	77
--	----

Measles Virus and Dendritic Cell Functions: How Specific Response Cohabites with Immunosuppression? C. SERVET-DELPAT, P.-O. VIDALAIN, H. VALENTIN, and C. RABOURDIN-COMBE	103
--	-----

Infection of Dendritic Cells by Lymphocytic Choriomeningitis Virus (LCMV) N. SEVILLA, S. KUNZ, D. MCGAVERN, and M.B.A. OLDSTONE	125
---	-----

The Interaction between Dendritic Cells and Herpes Simplex Virus-1 D. KOBELT, M. LECHMANN, and A. STEINKASSERER	145
---	-----

Part 2: Dendritic Cells and Immune-Intervention Strategies

Dendritic Cell-Based Immunotherapy T.G. BERGER and E.S. SCHULTZ	163
---	-----

Dendritic Cell Vaccination and Viral Infection – Animal Models B. LUDEWIG	199
---	-----

Interplay Between Human Papilloma Viruses and Dendritic Cells R. OFFRINGA, A. DE JONG, R.E.M. TOES, S.H. VAN DER BURG, and C.J.M. MELIEF	215
Viral Vectors for Dendritic Cell-Based Immunotherapy J. HUMRICH and L. JENNE	241
Cross Presentation of Cell-Associated Antigens by Dendritic Cells M. LARSSON, J.F. FONTENEAU, and N. BHARDWAJ	261
Dendritic Cells and HCMV Cross Presentation G. ARRODE and C. DAVRINCHE	277
Subject Index	295

List of Contributors

(Their addresses can be found at the beginning of their respective chapters)

ARRODE, G.	1, 277	LECHMANN, M.	145
BERGER, T.G.	163	LUDEWIG, B.	199
BHARDWAJ, N.	261	MCGAVERN, D.	125
BICKHAM, K.	55	MELIEF, C.J.M.	215
DAVRINCHE, C.	277	MÜNZ, C.	55
DE JONG, A.	215	OFFRINGA, R.	215
FONTENEAU, J.F.	261	OLDSTONE, M.B.A.	125
GEIJTENBEEK, T.B.H.	31	POPE, M.	1
GRANELLI-PIPERNO, A.	1	RABOURDIN-COMBE, C.	103
HUMRICH, J.	241	RACZ, P.	1
IGNATIUS, R.	1	SCHNEIDER-SCHAULIES, S.	77
JENNE, L.	241	SCHULTZ, E.S.	163
KLAGGE, I.M.	77	SERVET-DELPRAT, C.	103
KOBELT, D.	145	SEVILLA, N.	125
KUNZ, S.	125	STEINKASSERER, A.	145
LARSSON, M.	261	STEINMAN, R.M.	1

TENNER-RACZ, K. 1

VALENTIN, H. 103

TER MEULEN, V. 77

VAN DER BURG, S.H. 215

TOES, R.E.M. 215

VAN KOOYK, Y. 31

TRUMPFHELLER, C. 1

VIDALAIN, P.-O. 103